FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatm... (nj.com target

FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125

Date:9/22/2007

nj.com" target="_new">http://www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Media Contact: Pamela Van Houten

Office: 908-541-4137

Mobile: 908-295-7367

Investor Contacts: Louise Mehrotra (732) 524-6491

Stan Panasewicz (732) 524-2524

Lesley Fishman (732) 524-3922

SOURCE Tibotec Pharmaceuticals Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Mexico Supreme Court Accepts Petition To Review Mexico City Law Legalizing Abortion During First Three Months Gestation
2. Novartis files application with FDA for Zometa
3. Morepan to file new drug applications with the USFDA
4. Mini motor for micromedical applications
5. Perfusion bioreactor could enhance stem cell research and application in the future
6. Prostate Cancer Can Be Treated By Application Of LASER Technology
7. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
8. Venus Remedies Files 5th International Patent Application
9. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
10. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
11. New Drug Application Submitted for Investigational Antibiotic Doripenem

Post Your Comments:

(Date:11/20/2009).... 20 Following a recall by Unileve...from sale Shedd,s Country Crock ® Side Dishes...Crock ® Side Dishes DELUXE Four Cheese Pasta ...following code dates and UPCs are affected: ,, ...heddar Broccoli Rice 21 oz, UPC 027400218316, Best...

(Date:11/20/2009)...PRNewswire-USNewswire/ -- The American Dental Asso...dministration (FDA) to establish appropriate class...iting concern about the safety of whitening produc... of professional consultation or examination by a ... of chemically based tooth whitening or bleaching ...

(Date:11/20/2009)...., Nov. 20 Samuel Gladd...ine what it means to be "happy" during the holiday...cialty in family counseling and chair of the Depar...dding says research shows that it is the pressure ...epression during the holidays. ,, That,s why he...

(Date:11/20/2009)...ne November 20 in the Journal of the National Can... hopes that often appear in news coverage of cance...th the media and journals to help alleviate the pr...n Woloshin, M.D., M.S., of Center for Medicine and...olicy and Clinical Practice in New Hampshire, and ...

(Date:11/20/2009)...ber 20, 2009Emergency medical service (EMS) provid...00 cardiac arrests each year. Only 5 to 10 percen.... Better quality cardiopulmonary resuscitation (C...ssociated with better patient outcome. The Resusc...linical research network to study prehospital trea...

Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2 Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2 Health News:Why Holidays Don't Have To Be 'Happy' 2 Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2 Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2 Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3

[0] Stop & Shop Alerts Customers to Voluntary Recall by Unilever [0] American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products [0] Why Holidays Don't Have To Be 'Happy'[0] Promoting healthy skepticism in the news: Helping journalists get it right [0] Effect of real-time CPR feedback reported at resuscitation science symposium

...ch 5 Peregrine Pharmaceuticals, Inc. (Nasdaq: P...ancial results for the third quarter of fiscal yea... host a conference call and webcast to discuss the... 2009 and will review recent operating highlights....

...eives EU and US Approvals for Intravenous Formulat...l Temozolomide Sachet Presentation , , KENILWORTH...: SGP ) today announced that the European Commis...emozolomide is marketed as TEMODAL(R) in the EU an...

... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) tod...l year 2008 financial results after the NASDAQ Glo...at same afternoon, Jack Lief, Arena,s President an.... Eastern Time (2:00 p.m. Pacific Time) to discuss...

...., March 5 Smith & Nephew Inc,s Advanced Woun...y announced the U.S. launch of its next Negative P...SYS (TM) GO, designed to address the needs of cli...wound care. The U.S. Food and Drug Administration ...

...acquisition of NMHC drives GAAP earnings per share...4 2008, up from $6.5 million in Q4, 2007, ,...C Health Solutions Corp. ("SXC" or the "Company") ... in U.S. dollars unless otherwise indicated. , "20...

...e demand for a reliable, non-invasive, efficient a...s, lifestyles is boosting interest in bone growth ...t is however still small, as clinicians have felt ... research papers to substantiate the efficacy of t...

Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009 Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients SXC Health solutions announces strong fourth quarter and year end financial results According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators

(Date:11/20/2009)...swire/ -- ,, Reportlinker.com announces that a ...alogue. ,, Global Markets for Breast Biopsy De...164741/Global-Markets-for-Breast-Biopsy-Devices-20...p;utm_campaign=prnewswire ,, The global marke...oaded core needle market and vacuum assisted breas...

(Date:11/20/2009)...re-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX )...ef Executive Officer, and Greg Browne, Chief Finan...r Jaffray Health Care Conference in New York on We...nference session and webcast will be audio only an...ay will host a webcast of the presentation live an...

(Date:11/19/2009)...ewswire/ -- Warner Chilcott plc (Nasdaq: WCRX ) t...nced secondary offering of 20,000,000 of its ordin...share. The selling shareholders include funds aff...anking, J.P. Morgan Partners (advised by CCMP Capi...er institutional investors and members of the Comp...

Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2 Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2 Warner Chilcott Prices Secondary Equity Offering 2 Warner Chilcott Prices Secondary Equity Offering 3 Warner Chilcott Prices Secondary Equity Offering 4 NHLBI awards 2411 million for molecular roadmap to chronic lung diseases 10289 1 NHLBI awards 2411 million for molecular roadmap to chronic lung diseases 10289 2 Long Term Back Pain Not Inevitable Study Finds 59075 1 Long Term Back Pain Not Inevitable Study Finds 59075 2 Endovenous Laser Therapy Used for Treatment of Varicose Veins 59071 1 Endovenous Laser Therapy Used for Treatment of Varicose Veins 59071 2

[0] Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 [0] Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference [0] Warner Chilcott Prices Secondary Equity Offering

...onference Call on Monday, April 14, at 8:30 a.m. E...m.com , CARLSBAD, Calif., April 14 Isis,Pharmace...l results from its,ongoing Phase 2 open-label exte...amilial hypercholesterolemia (FH). In FH patients ...e safety profile of the drug,continues to be encou...

...3 Researchers from the,Barbara Ann Karmanos Cance...owing that adding curcumin or resveratrol to conve...ing the growth of chemo-resistant colon cancer,cel...merican Association,for Cancer Research (AACR) Ann...om.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITU...

Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6 Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells

...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...

Medicine Products:

Chromium, Urine Cholinesterase, Serum or Plasma Cholesterol, Serum or Plasma Chloride, Urine

FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatm...(nj.com target _new http://www.jnj.com ...),Health